You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
The assay, called the single telomere absolute-length rapid (STAR) assay, uses Fluidigm microfluidic chips and was found to be accurate and sensitive.
JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.
The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.
The firm's Continuum system is fully automated and performs the entire digital PCR workflow in a single instrument.
In PLOS this week: computational strategy to study human population histories, BRAF mutational load in melanoma and disease progression, and more.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The firm will apply the funds to development of a next generation of its digital PCR system as well as expansion in Asia.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.